---
title: "Johnson & Johnson's Tremfya reduces axial psoriatic arthritis symptoms in Phase 4 trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306278632.md"
description: "Johnson & Johnson's Tremfya met key endpoints in the Phase 4 STAR trial for adults with axial psoriatic arthritis. The treatment significantly improved axial symptoms compared to placebo, with MRI scans confirming reduced sacroiliac joint inflammation. No new safety signals were identified, supporting the drug's established safety profile. These late-breaking results are being presented at the Emirates Society for Rheumatology Annual Meeting."
datetime: "2026-11-20T13:01:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306278632.md)
  - [en](https://longbridge.com/en/news/306278632.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306278632.md)
generator: "portal-rs"
---

# Johnson & Johnson's Tremfya reduces axial psoriatic arthritis symptoms in Phase 4 trial

-   Johnson & Johnson’s Tremfya met key endpoints in the Phase 4 STAR trial in adults with psoriatic arthritis involving the spine. \* Treatment significantly improved axial symptoms versus placebo, with MRI scans confirming reduced sacroiliac joint inflammation. \* No new safety signals emerged; findings supported Tremfya’s established safety profile. \* Late-breaking results are being presented at the Emirates Society for Rheumatology Annual Meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611200800PR\_NEWS\_USPR\_\_\_\_\_NY02933) on November 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [J&J says Tremfya posts sustained Crohn’s remission through 3 years in Phase 3 GALAXI studies](https://longbridge.com/en/news/301752007.md)
- [Johnson & Johnson says long-term data boosts Icotyde for plaque psoriasis](https://longbridge.com/en/news/301420344.md)
- [US FDA declines to approve Capricor's cell therapy for Duchenne muscular dystrophy; shares slump](https://longbridge.com/en/news/306337632.md)
- [AI solves 167-year-old maths problem, Anthropic researcher claims](https://longbridge.com/en/news/306318851.md)
- [Lumentum President of Global Business Units Wupen Yuen Reports Sale of $833,200 in Common Shares](https://longbridge.com/en/news/306338831.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**